Sanofi has secured its second acquisition this month in orphan diseases and hematology by offering €3.9bn ($4.8bn) for Nanobody drug development Ablynx NV; the deal has eclipsed a previous bid for Ablynx made by Sanofi's diabetes competitor Novo Nordisk AS.
When Novo Nordisk went public earlier in January about its two rebuffed attempts to buy Ablynx – a company with...








